Physician profile
Kyle L Lloyd
NPI 1275679508
$9,709.63
in general payments reported to CMS, 2019-2025
42 companies · $853 in 2025
The $853 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,304 · 2020: $1,630 · 2021: $1,961 · 2022: $960 · 2023: $989 · 2024: $1,012 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,161.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $1,100.19 | 2019-2022 | |
| Lilly USA, LLC | $1,041.32 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $995.05 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $858.69 | 2019-2024 | Spravato |
| Glaxosmithkline, LLC. | $651.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $621.80 | 2019-2025 | |
| Amgen INC. | $535.07 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $439.64 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Abbvie INC. | $374.40 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $233.21 | 2023-2024 | Quviviq |
| Medicure Pharma INC. | $192.35 | 2020-2023 | Zypitamag |
| Allergan, INC. | $189.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.35 | 2019-2025 | Ofev |
| Sumitomo Pharma America, INC. | $110.74 | 2023-2024 | Gemtesa |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.